Key result
Genetic reanalysis of arrhythmogenic cardiomyopathy variants reclassifies ~31% after 5 years, mostly increasing certainty.
Why the study?
Genetic interpretation of rare variants associated with arrhythmogenic cardiomyopathy is essential, but how often variant reanalysis is necessary remains undefined.
Does periodic genetic reanalysis of rare variants every 5 years improve diagnostic classification in patients with arrhythmogenic cardiomyopathy?
Observational (n=39)
Does periodic genetic reanalysis of rare variants every 5 years improve diagnostic classification in patients with arrhythmogenic cardiomyopathy?
Periodic re-evaluation of rare variants in arrhythmogenic cardiomyopathy is necessary, as 5-year updates reclassified approximately 31% of cases and significantly reduced diagnostic uncertainty.
Hypothesis-generating for 5-year ACM variant reanalysis; prospective studies needed before clinical adoption.
Genetic interpretation of rare variants associated with arrhythmogenic cardiomyopathy (ACM) is essential due to their diagnostic implications. New data may relabel previous variant classifications, but how often reanalysis is necessary remains undefined. Five years ago, 39 rare ACM-related variants were identified in patients with features of cardiomyopathy. These variants were classified following the American College of Medical Genetics and Genomics' guidelines. In the present study, we reevaluated these rare variants including novel available data. All cases carried one rare variant classified as being of ambiguous significance (82.05%) or likely pathogenic (17.95%) in 2016. In our comprehensive reanalysis, the classification of 30.77% of these variants changed, mainly due to updated global frequencies. As in 2016, nowadays most variants were classified as having an uncertain role (64.1%), but the proportion of variants with an uncertain role was significantly decreased (17.95%). The percentage of rare variants classified as potentially deleterious increased from 17.95% to 23.07%. Moreover, 83.33% of reclassified variants gained certainty. We propose that periodic genetic reanalysis of all rare variants associated with arrhythmogenic cardiomyopathy should be undertaken at least once every five years. Defining the roles of rare variants may help clinicians obtain a definite diagnosis.
No takes yet. Share an insight, caveat, or question.
Vallverdú-Prats et al. (2021) conducted an observational in Arrhythmogenic cardiomyopathy (ACM) (n=39). Genetic reanalysis of rare variants vs. Original classification in 2016 was evaluated on Reclassification rate of rare variants. Genetic reanalysis of rare variants associated with arrhythmogenic cardiomyopathy after five years reclassified 30.77% of the variants, with 83.33% of those gaining diagnostic certainty.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: